Chinese Regulator Approves DAXXIFY for Registration
The National Medical Products Administration has approved for registration, DAXXIFY, a botulinum toxin type A for injection, used to temporary improve the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult patients, a Monday filing with the Hong Kong Exchange said.
Sisram Medical's (HKG:1696) subsidiary was given the sub-license of the product by Shanghai Fosun Pharmaceutical Industrial Development for the rights to use, import, sell, and commercialize in the region.
The original licensor, the US-based Revance Therapeutics, is the right holder of the product in the region.
The company's shares were down 7% on Monday's close.
Price (HKD): $3.19, Change: $-0.24, Percent Change: -7.00%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。